Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to be releasing its results on Friday, November 13th. Analysts expect Panbela Therapeutics to announce earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Price Performance
Shares of PBLA opened at $0.00 on Thursday. Panbela Therapeutics has a 1-year low of $0.00 and a 1-year high of $0.10. The firm has a 50 day simple moving average of $0.01 and a 200-day simple moving average of $0.01.
About Panbela Therapeutics
Panbela Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research has centered on treatments that target polyamine metabolism, a biological process associated with tumor growth and cancer progression. Panbela’s lead investigational product has been ivospemin, formerly known as SBP-101, which has been studied in combination with standard treatments for pancreatic ductal adenocarcinoma and other solid tumors. The company has also pursued eflornithine-based programs, including combinations intended to support cancer treatment and prevention strategies.
Featured Stories
- Five stocks we like better than Panbela Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
